Commercializing and shipping the newly FDA-cleared next-generation Tablo platform, which is the first dialysis system designed to meet the FDA's rigorous June 2025 cybersecurity requirements.

Expected impact: Expected to drive a significant ramp-up in console shipments and recurring consumable revenue starting in the second half of 2026, while establishing a strong competitive moat through advanced cybersecurity compliance.

Transitioning the commercial sales strategy to an enterprise-focused model to improve capital sales predictability and secure larger, multi-year hospital and health system contracts.

Expected impact: Aims to improve capital sales predictability, reduce quarterly revenue lumpiness, and secure larger, multi-year commitments from major health systems.

Implementing disciplined spending controls, streamlining manufacturing processes, and reducing overhead to narrow operating losses.

Expected impact: Expected to reduce full-year 2026 cash usage to under $40 million (a 15% improvement over prior expectations) and accelerate the timeline to self-funded profitability.